ADAP Adaptimmune Therapeutics plc -

4.11
-0.08  -1.91%
Previous Close 4.19
Open 0.00
Price To book 0.00
Market Cap N/A
Shares 0
Volume 40,057
Short Ratio 0.00
Av. Daily Volume 114,250

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Further trials planned for 2H 2016
NY-ESO T-cell therapy
Ovarian cancer
Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Further trials planned for 1H 2017.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)

Latest News

  1. Adaptimmune to Participate in Upcoming Investor Conference
  2. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
  4. Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
  5. Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
  6. These 5 Stocks Under $10 Could Make You a Lot of Money
  7. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
  8. Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
  9. Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
  10. Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
  11. Is Adaptimmune Therapeutics PLC (ADAP) A Good Stock To Buy?
  12. How Verso Corporation (VRS) Stacks Up Against Its Peers
  13. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
  15. Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
  16. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Termination of a Material Definitive Agreement
  17. ADAPTIMMUNE THERAPEUTICS PLC Financials
  18. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  19. Edited Transcript of ADAP earnings conference call or presentation 10-Nov-16 1:00pm GMT
  20. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements